Ascendis Pharma A/S (NASDAQ:ASND) Given New $224.00 Price Target at Oppenheimer

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target lifted by Oppenheimer from $215.00 to $224.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an "outperform" rating on the biotechnology company's stock. Oppenheimer's target price suggests a potential upside of 31.15% from the stock's previous close.

ASND has been the topic of a number of other reports. Wedbush boosted their price target on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Bank of America lifted their target price on shares of Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a research note on Monday. Royal Bank of Canada lifted their target price on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Evercore ISI lifted their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Finally, The Goldman Sachs Group lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and an average target price of $220.67.

Ascendis Pharma A/S Price Performance

ASND traded down $0.12 on Friday, reaching $170.80. 369,830 shares of the company's stock were exchanged, compared to its average volume of 493,293. The stock has a market cap of $10.43 billion, a PE ratio of -24.06 and a beta of 0.37. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $183.00. The stock's fifty day moving average price is $161.68 and its 200-day moving average price is $147.98.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to analysts' expectations of $98.56 million. As a group, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ascendis Pharma A/S during the fourth quarter valued at about $28,000. Jones Financial Companies Lllp grew its holdings in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 197 shares in the last quarter. Brooklyn Investment Group grew its holdings in shares of Ascendis Pharma A/S by 332.9% in the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 273 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 328 shares in the last quarter. Finally, Quarry LP acquired a new position in shares of Ascendis Pharma A/S in the fourth quarter valued at approximately $96,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.